Intellectual Product – Page 26

Unlocking Direct-to-Consumer (DTC) Adoption: Leveraging Telehealth Programs for Enhanced Healthcare Access” ###

11 months ago talkbio0Tagged Adoption, clinical networks, Consumer health, Consumption of goods, Direct-to-Consumer, DTC, Health care facility, perspectives, pharma leaders, Policy, Primary Health Care, Reimbursement models, Services, Telemedicine, virtual care platforms

Direct-to-Consumer (DTC) digital health, Telehealth adoption, Virtual care platforms, Clinical networks, Consumer health and pharma leaders, Telemedicine services, Healthcare consumption, Primary care, Reimbursement models, Policy perspectives

Senior Manager Commercial Analytics Respiratory: Key Requirements and Responsibilities

11 months ago talkbio0Tagged biopharmaceutical industry, commercial, respiratory division, Sales - occupational activity, Senior - Suffix, Strategic Planning, tools

Senior Manager Commercial Analytics Respiratory, biopharmaceutical industry, commercial analytics, therapeutic areas, respiratory division, strategic planning, sales tools.

Innovent Biologics’ Picankibart Achieves Success in Phase III CLEAR-1 Study for Moderate to Severe Plaque Psoriasis

12 months ago talkbio0Tagged Biological Factors, Center for Drug Evaluation, Chronic small plaque psoriasis, Class, drug application, Innovent, Interleukin-23 Subunit p19, Moderate (severity modifier), National Medical Product Administration, Phase III CLEAR-1 Study, picankibart

Innovent Biologics, picankibart, Phase III CLEAR-1 study, moderate to severe plaque psoriasis, IL-23p19 class, new drug application, Center for Drug Evaluation, National Medical Product Administration.

Insmed’s Stocks Skyrocket Following Triumphant Phase III Results for Brensocatib in Bronchiectasis Treatment

12 months ago talkbio0Tagged Approved, brensocatib, Bronchiectasis, Insmed, Lung diseases, Market, New Drug Application, Phase 3 Clinical Trials, surge, United States Food and Drug Administration

Insmed, brensocatib, bronchiectasis, Phase III trial, lung disease, stock surge, New Drug Application, FDA approval, market value

Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy

12 months ago talkbio0Tagged Adenocarcinoma of lung (disorder), Antigens, Biosciences, Cancer Therapeutic Procedure, Cartography, Cervical Atlas, Drug Development, Gilead Sciences, Neoplasms, summit, targets, Technology Platform, Triple Negative Breast Neoplasms

Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.

Revolutionizing CAR-Ts: The Future of Automation and Decentralization in Cell and Gene Therapy Manufacturing

12 months ago12 months ago talkbio0Tagged Advanced therapies, Automation, CAR-Ts, Cells, Decentralization, Digital X-ray, gene therapy, Manufacture, Patient-Centered Care, Precision Medicine, Preventive monitoring, quality management systems, real-time, Regulatory Compliance, Supply chain logistics

Automation, Decentralization, CAR-Ts, Cell and gene therapy manufacturing, Advanced therapies, Personalized medicine, Regulatory compliance, Quality management systems, Supply chain logistics, Digital solutions, Real-time monitoring, Patient-centered care